Guillain-Barré syndrome: epidemiology, pathophysiology and management.

Abstract:

:Guillain-Barré syndrome (GBS) is clinically defined as an acute peripheral neuropathy causing limb weakness that progresses over a time period of days or, at the most, up to 4 weeks. GBS occurs throughout the world with a median annual incidence of 1.3 cases per population of 100 000, with men being more frequently affected than women. GBS is considered to be an autoimmune disease triggered by a preceding bacterial or viral infection. Campylobacter jejuni, cytomegalovirus, Epstein-Barr virus and Mycoplasma pneumoniae are commonly identified antecedent pathogens. In the acute motor axonal neuropathy (AMAN) form of GBS, the infecting organisms probably share homologous epitopes to a component of the peripheral nerves (molecular mimicry) and, therefore, the immune responses cross-react with the nerves causing axonal degeneration; the target molecules in AMAN are likely to be gangliosides GM1, GM1b, GD1a and GalNAc-GD1a expressed on the motor axolemma. In the acute inflammatory demyelinating polyneuropathy (AIDP) form, immune system reactions against target epitopes in Schwann cells or myelin result in demyelination; however, the exact target molecules in the case of AIDP have not yet been identified. AIDP is by far the most common form of GBS in Europe and North America, whereas AMAN occurs more frequently in east Asia (China and Japan). The prognosis of GBS is generally favourable, but it is a serious disease with a mortality of approximately 10% and approximately 20% of patients are left with severe disability. Treatment of GBS is subdivided into: (i) the management of severely paralysed patients with intensive care and ventilatory support; and (ii) specific immunomodulating treatments that shorten the progressive course of GBS, presumably by limiting nerve damage. High-dose intravenous immunoglobulin (IVIg) therapy and plasma exchange aid more rapid resolution of the disease. The predominant mechanisms by which IVIg therapy exerts its action appear to be a combined effect of complement inactivation, neutralisation of idiotypic antibodies, cytokine inhibition and saturation of Fc receptors on macrophages. Corticosteroids alone do not alter the outcome of GBS.

journal_name

Drugs

journal_title

Drugs

authors

Kuwabara S

doi

10.2165/00003495-200464060-00003

subject

Has Abstract

pub_date

2004-01-01 00:00:00

pages

597-610

issue

6

eissn

0012-6667

issn

1179-1950

pii

6463

journal_volume

64

pub_type

杂志文章,评审

相关文献

DRUGS文献大全
  • Candesartan cilexetil: an update of its use in essential hypertension.

    abstract:UNLABELLED:Candesartan cilexetil is converted to the angiotensin II receptor antagonist candesartan during absorption from the gastrointestinal tract. The selective and competitive binding of candesartan to the angiotensin II type 1 (AT(1)) receptor prevents binding of angiotensin II, a key mediator in the renin-angiot...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200262080-00016

    authors: Easthope SE,Jarvis B

    更新日期:2002-01-01 00:00:00

  • Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.

    abstract::Coronary arterial thrombolysis is becoming an established treatment of acute myocardial infarction. If given early enough, it recanalises occluded coronary arteries, salvages myocardial function and reduces mortality. A reduction of mortality in patients with acute myocardial infarction has now been demonstrated for s...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198938030-00003

    authors: Collen D,Lijnen HR,Todd PA,Goa KL

    更新日期:1989-09-01 00:00:00

  • The Emerging Role of PI3K Inhibitors in the Treatment of Hematological Malignancies: Preclinical Data and Clinical Progress to Date.

    abstract::The phosphoinositide 3-kinase (PI3K)/Akt/mTOR pathway is implicated in the pathogenesis of lymphoma. Deeper understanding of the diversity and biological impact of this pathway has led to the development of specific inhibitors to this pathway. Preclinical data in cell lines, patient samples and disease models have bro...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-016-0565-4

    authors: Seiler T,Hutter G,Dreyling M

    更新日期:2016-04-01 00:00:00

  • Bromocriptine in the treatment of hypogonadism and male impotence.

    abstract::A rapid, practical diagnostic scheme is the key to selecting proper candidates for treatment with bromocriptine. The evaluation centres around assays for prolactin and follicle stimulating hormone, polytomography and computerised axial tomography of the sella turcica and parasellar regions, and the ergot alkaloid, bro...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197917050-00004

    authors: March CM

    更新日期:1979-05-01 00:00:00

  • Current treatment recommendations for topical burn therapy.

    abstract::Infections in burn patients continue to be the primary source of morbidity and mortality. Topical antimicrobial therapy remains the single most important component of wound care in hospitalised burn patients. The goal of prophylactic topical antimicrobial therapy is to control microbial colonisation and prevent burn w...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199040030-00004

    authors: Monafo WW,West MA

    更新日期:1990-09-01 00:00:00

  • Influence of fibrinogen on cardiovascular disease.

    abstract::Results from prevalence, case-control, angiographic and echocardiographic investigations incriminate elevated fibrinogen levels as a strong independent risk factor for the occurrence of initial and recurrent cardiovascular events. Average fibrinogen levels are higher in women and persons with other risk factors includ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199700543-00006

    authors: Kannel WB

    更新日期:1997-01-01 00:00:00

  • Antacids and ulcer healing. A review of the evidence.

    abstract::There have been a number of controlled trials of antacids in the treatment of patients with peptic ulcer disease. As a general rule the size of studies has been small and there have been difficulties ensuring adequate binding, because of the formulation and taste of the antacids. Despite these difficulties, antacids a...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,评审

    doi:10.2165/00003495-199142020-00003

    authors: Walt RP,Langman MJ

    更新日期:1991-08-01 00:00:00

  • The use of fluoroquinolones in sexually transmitted diseases in Southeast Asia.

    abstract::This paper reviews the use of the fluoroquinolone antibiotics in the management of sexually transmitted diseases (STD) in Southeast Asia. Numerous clinical trials performed in the region have shown that the quinolones are highly effective for treating uncomplicated gonorrhoea. Norfloxacin 800 mg, ofloxacin 400 mg, cip...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199500492-00019

    authors: Sivayathorn A

    更新日期:1995-01-01 00:00:00

  • Diagnosis and Treatment of Non-24-h Sleep-Wake Disorder in the Blind.

    abstract::Non-24-h sleep-wake disorder (non-24) is a circadian rhythm disorder occurring in 55-70% of totally blind individuals (those lacking conscious light perception) in which the 24-h biological clock (central, hypothalamic, circadian pacemaker) is no longer synchronized, or entrained, to the 24-h day. Instead, the overt r...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-017-0707-3

    authors: Emens JS,Eastman CI

    更新日期:2017-04-01 00:00:00

  • Rupatadine: a review of its use in the management of allergic disorders.

    abstract::Rupatadine (Rupafin, Rinialer, Rupax, Alergoliber) is a selective oral histamine H(1)-receptor antagonist that has also been shown to have platelet-activating factor (PAF) antagonist activity in vitro. It is indicated for use in seasonal allergic rhinitis (SAR), perennial allergic rhinitis (PAR) and chronic idiopathic...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200767030-00008

    authors: Keam SJ,Plosker GL

    更新日期:2007-01-01 00:00:00

  • Valsartan/hydrochlorothiazide.

    abstract::Valsartan/hydrochlorothiazide (HCTZ) combines an angiotensin II AT1 receptor blocker with a thiazide diuretic to produce additive blood pressure reductions without major effects on heart rate. HCTZ did not significantly alter valsartan pharmacokinetics; during combination therapy, HCTZ pharmacokinetics differed from t...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199957050-00008

    authors: Langtry HD,McClellan KJ

    更新日期:1999-05-01 00:00:00

  • Azacitidine: a review of its use in higher-risk myelodysplastic syndromes/acute myeloid leukaemia.

    abstract::Azacitidine (Vidaza) is a pyrimidine nucleoside analogue of cytidine. Subcutaneous azacitidine was recently approved in the EU for the treatment of adults who are not eligible for haematopoietic stem cell transplantation and who have intermediate-2-risk or high-risk myelodysplastic syndromes (MDS) [according to Intern...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11202840-000000000-00000

    authors: Keating GM

    更新日期:2009-01-01 00:00:00

  • Hypertension in pregnancy. Pathophysiology and management.

    abstract::Hypertension in pregnancy has implications for both maternal and fetal welfare. Extrapolation from concepts of mechanisms operating in hypertension in general to pregnancy-related hypertension is not justified. In the latter, the major features are a hyper-adrenergic state, plasma volume reduction and an increased sys...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198428020-00005

    authors: Lubbe WF

    更新日期:1984-08-01 00:00:00

  • Rilpivirine.

    abstract::Rilpivirine is an orally administered, non-nucleoside reverse transcriptase inhibitor that is a component drug in combination therapy for antiretroviral-naive patients with HIV-1 infection. The randomized, double-blind, double-dummy, multinational ECHO and THRIVE trials in antiretroviral-naive adult patients with HIV-...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11208590-000000000-00000

    authors: Sanford M

    更新日期:2012-03-05 00:00:00

  • Emerging options in the treatment of bipolar disorders.

    abstract::Bipolar disorder is a common and severe condition, and has a clinical outcome that is frequently sub-optimal. Only a small number of therapeutic options are currently available for the disorder. A growing range of novel therapeutic options for the treatment of bipolar disorder are under investigation. These include th...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200161100-00004

    authors: Berk M,Segal J,Janet L,Vorster M

    更新日期:2001-01-01 00:00:00

  • Cidofovir.

    abstract::Cidofovir is a nucleotide analogue which inhibits viral DNA polymerase and is effective against human cytomegalovirus (CMV) infection. It is phosphorylated to its active form by cellular enzymes. With the long intracellular half-life of its metabolites, cidofovir can be administered weekly during induction and every o...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199652020-00006

    authors: Lea AP,Bryson HM

    更新日期:1996-08-01 00:00:00

  • Second-generation antihistamines: a comparative review.

    abstract::Second-generation histamine H1 receptor antagonists (antihistamines) have been developed to reduce or eliminate the sedation and anticholinergic adverse effects that occur with older H1 receptor antagonists. This article evaluates second-generation antihistamines, including acrivastine, astemizole, azelastine, cetiriz...

    journal_title:Drugs

    pub_type: 杂志文章,meta分析

    doi:10.2165/00003495-199957010-00004

    authors: Slater JW,Zechnich AD,Haxby DG

    更新日期:1999-01-01 00:00:00

  • Transdermal clonidine. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.

    abstract::The clonidine transdermal therapeutic system (TTS) is a cutaneous delivery device which provides therapeutically effective doses of clonidine at a constant rate over 7 days. In clinical trials it reduces blood pressure in patients with mild to moderate hypertension as effectively as oral clonidine but with greater sta...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198835020-00003

    authors: Langley MS,Heel RC

    更新日期:1988-02-01 00:00:00

  • The coming era of quadrivalent human influenza vaccines: who will benefit?

    abstract::Influenza vaccines form the mainstay of public health and personal protection against infection with seasonal influenza viruses. These vaccines are designed to protect people against infection with the currently circulating influenza viruses. Since the late 1970s, this has required the use of a trivalent vaccine consi...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/11641110-000000000-00000

    authors: Barr IG,Jelley LL

    更新日期:2012-12-03 00:00:00

  • Studies with temocillin in the hamster model of antibiotic-associated colitis.

    abstract::The studies reported here were designed to ascertain whether or not the new beta-lactam antibiotic, temocillin, would produce antibiotic-associated colitis in the hamster. The experiments were controlled with clindamycin and cefoxitin, which are known to induce antibiotic-associated colitis experimentally and clinical...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198500295-00012

    authors: Boon RJ,Beale AS

    更新日期:1985-01-01 00:00:00

  • Canagliflozin: first global approval.

    abstract::Canagliflozin (Invokana™), an oral selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, is under global development with Mitsubishi Tanabe Pharma and Janssen Pharmaceuticals, a subsidiary of Johnson and Johnson, for the treatment of type 2 diabetes mellitus. SGLT2 are mainly located in the proximal tubule of t...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-013-0064-9

    authors: Elkinson S,Scott LJ

    更新日期:2013-06-01 00:00:00

  • Alitretinoin: A Review in Severe Chronic Hand Eczema.

    abstract::Chronic hand eczema is a common but frequently disabling skin condition which poses a significant social and economic burden. Although skin protection measures and topical therapies are fundamental in its management, some patients are refractory to first-line therapy with topical corticosteroids and require systemic t...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-016-0621-0

    authors: Blair HA,Scott LJ

    更新日期:2016-09-01 00:00:00

  • Clinical potential of topical corticosteroids.

    abstract::The treatment of a variety of inflammatory skin diseases was greatly changed by the introduction, in the early 1950s, of corticosteroids for topical use. Topical corticosteroids are still the most widely used drugs in dermatology, and many preparations with quite different potencies are now available. However, attempt...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198800365-00008

    authors: Ortonne JP

    更新日期:1988-01-01 00:00:00

  • Liposomal drug formulations. Rationale for development and what we can expect for the future.

    abstract::Liposomes are versatile drug carriers which can be used to solve problems of drug solubility, instability and rapid degradation. Both hydrophilic and hydrophobic drugs can be associated with liposomes and special techniques have been developed for the efficient loading of weak acids and weak bases into liposomes. Lipo...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199856050-00001

    authors: Allen TM

    更新日期:1998-11-01 00:00:00

  • Acitretin : A Review of its Pharmacology and Therapeutic Use.

    abstract:SYNOPSIS:Acitretin (etretin), a second generation monoaromatic retinoid for use in the treatment of severe psoriasis and other dermatoses, is the major active metabolite of etretinate and possesses a similar therapeutic index; i.e. a similar ratio of clinical efficacy to adverse effects. When used alone at a maintenanc...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-199243040-00010

    authors: Pilkington T,Brogden RN

    更新日期:1992-04-01 00:00:00

  • Effects of enalapril on clinical status, biochemistry, exercise performance and haemodynamics in heart failure.

    abstract::The effects of enalapril on clinical well-being, treadmill exercise performance, haemodynamic measurements, hormone levels, and plasma biochemistry in patients with moderate heart failure, were assessed in a 12-week placebo-controlled, double-blind study. Maintenance frusemide and digoxin treatment was continued throu...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章

    doi:10.2165/00003495-198500301-00011

    authors: Webster MW,Fitzpatrick MA,Hamilton EJ,Nicholls MG,Ikram H,Espiner EA,Wells JE

    更新日期:1985-01-01 00:00:00

  • The management of epilepsy in the 1990s. Acquisitions, uncertainties and priorities for future research.

    abstract::The pharmacological treatment of epilepsy has made considerable progress during the last decade, due to improved knowledge of the clinical pharmacology of individual drugs, acquisition of new information on the factors affecting response and need for drug treatment, and development of promising new agents. Once a clin...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199549050-00004

    authors: Beghi E,Perucca E

    更新日期:1995-05-01 00:00:00

  • Pharmacology and therapeutic use of calcitonin.

    abstract::Calcitonin is a peptide hormone secreted by the C-cells of the thyroid gland. A major physiological function of the hormone appears to be the protection of the skeleton against resorption in humans. It thus opposes the resorptive actions of parathyroid hormone and 1,25 dihydroxyvitamin D. This action is utilised pharm...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198121040-00002

    authors: Stevenson JC,Evans IM

    更新日期:1981-04-01 00:00:00

  • Oral etoposide in lymphoma.

    abstract::Etoposide is one of the most active agents for the therapy of lymphomas. Oral etoposide has proven to be active in and clearly beneficial for patients with previously treated lymphomas. The optimal dose and schedule of oral etoposide for use in combination chemotherapy are still uncertain, but low daily doses (50 to 1...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199958003-00006

    authors: Greco FA

    更新日期:1999-01-01 00:00:00

  • Current, new and future treatments in dyslipidaemia and atherosclerosis.

    abstract::The new therapeutic options available to clinicians treating dyslipidaemia in the last decade have enabled effective treatment for many patients. The development of the HMG-CoA reductase inhibitors (statins) have been a major advance in that they possess multiple pharmacological effects (pleiotropic effects) resulting...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200060010-00005

    authors: Chong PH,Bachenheimer BS

    更新日期:2000-07-01 00:00:00